The synthetically lethal relationship between RAD52 and BRCA was first exploited using an oligopeptide aptamer to inhibit RAD52 in BRCA-downregulated acute myeloid leukemia cells. This evidence concerns the gene RAD52 and acute myeloid leukemia.